BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...

BTIG analyst Gregory Lewis (JO:LEWJ) revised the price target for Blue Bird Corp (NASDAQ:BLBD) shares to $45.00, down from the previous target of $55.00, while reaffirming a Buy rating on the stock.

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

Performant Healthcare, Inc. (Nasdaq: PHLT) ("Performant"), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, announced today that it will ...

BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday, February 12, 2025. The firm expects ...

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

While value offerings are helping improve sales, some franchisees have yet to fully recover their visits and sales comps as ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently ...

StockNews.com upgraded shares of Boot Barn (NYSE:BOOT – Free Report) from a sell rating to a hold rating in a research report ...

We recently compiled a list of the 12 Biggest Lithium Stocks to Buy According to Hedge Funds. In this article, we are going ...